finanzen.net

Calypte Only Company with Full Menu of Tests.

Seite 143 von 144
neuester Beitrag: 03.03.11 19:06
eröffnet am: 08.04.05 22:44 von: Brokersince1. Anzahl Beiträge: 3593
neuester Beitrag: 03.03.11 19:06 von: schubby1 Leser gesamt: 136185
davon Heute: 17
bewertet mit 8 Sternen

Seite: 1 | ... | 140 | 141 | 142 |
| 144  

09.05.07 11:11

227 Postings, 5210 Tage calyritter_die_Ratteda bist wohl sprachlos broker was?

das alte stinkige rohr ist wohl schon lange nicht mehr richtig durchgeblasen worden!  

14.05.07 14:47
Calypte Appoints New Board Member
Monday May 14, 8:30 am ET


LAKE OSWEGO, Ore., May 14 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV), announced that its Board of Directors appointed Mr. Adel Karas as an independent member of the Company's Board of Directors effective May 8, 2007.
ADVERTISEMENT


Mr. Karas has over 35 years of experience, primarily on the international front, much of it in the market regions in which Calypte is targeting sales for its Aware(TM) HIV-1/2 Oral Fluid diagnostic tests. Since December 2005 Mr. Karas has worked as the Regional Director (Asia, Africa & Middle East) for the World Agency of Planetary Monitoring & Earthquake Risk Reduction (WAPMERR) based in Dubai, United Arab Emirates (UAE). WAPMERR is involved with disaster management and risk assessments.

Prior to his involvement with WAPMERR, in 2003 Mr. Karas co-founded and served as Managing Director of Strategic Energy Investment Group in Dubai. He started this group following his retirement from Petroleum Geo-Services (PGS) in Houston, Texas where he served as Senior Vice President of Business Development for two years before moving to Dubai where he set up and, for the next eight years, served as President of PGS for the Middle East Region. Mr. Karas served, as well, as the executive vice president for Grant Tensor Geophysical in Houston-Texas and as the president of Tensor Geophysical in Egypt. Mr. Karas attended AinShams University, University of Texas and University of Houston. He holds degrees in Geophysics and Operations Research as well as a Masters Degree in electrical engineering and an MBA.

Roger I. Gale, President and CEO of Calypte stated, "We are pleased to welcome Mr. Karas to our Board and look forward to his knowledge and guidance as we expand, with his help, into regions where our non-invasive HIV/AIDS rapid test is much needed, including the Middle East and Asia. Further, we expect his knowledge of and contacts in Thailand, where we have outsourced manufacturing, and Switzerland, where many key humanitarian agencies are headquartered, will help us facilitate our business opportunities as well. As Calypte focuses on the emerging HIV epidemic countries, I expect that Mr. Karas will play a vital role in Calypte's growth in those areas of the world. We intend to use his strong technical training - he is, quite simply, a quick study - and his many years of varied international experience, including establishing cross border entities and mergers and acquisitions. He has strong relationships with key business and governmental leaders in this area as well."

Mr. Karas commented, "I am honored to be a part of Calypte at this critical juncture - the start of its "journey" to quote management. I expect to be effective in assisting the Company from my own base of operations in Dubai. I consider Calypte a lean, point of care diagnostic testing company, today focused on HIV, but with the capability to do much more. My experience supports the Company's newly articulated strategy - that physical presence is essential; being on the ground regionally to aggressively get close to the customer and understand the uniqueness of the many regions in which Calypte operates."

"I personally took a company that was headquartered in Houston to Dubai, set up a regional center and then used the in-country advantage to capture a 50% market share. I believe Calypte's simple, accurate, non-invasive products will be well received in this part of the world. I have personally accompanied management and visited key business contacts in UAE and have seen for myself the strong interest Calypte's products generate," Mr. Karas continued.

About Calypte Biomedical:

Calypte Biomedical Corporation (http://www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV- 1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.


   Company Contact:                   Investor Relations Contact:
   Richard Brounstein,                Tim Clemensen,
   Executive Vice President           Rubenstein Investor Relations
   (971) 204-0282                     Phone: (212) 843-9337
   email: rbrounstein@calypte.com     email: tclemensen@rubensteinir.com




--------------------------------------------------
Source: Calypte Biomedical Corporation


 

14.05.07 15:54
2

40968 Postings, 7106 Tage Dr.UdoBroemmeRichtungsweisende Personalentscheidung.

Caly holt sich einen Katastrophenexperten an Bord :-)

Since December 2005 Mr. Karas has worked as the Regional Director (Asia, Africa & Middle East) for the World Agency of Planetary Monitoring & Earthquake Risk Reduction (WAPMERR) based in Dubai, United Arab Emirates (UAE). WAPMERR is involved with disaster management and risk assessments.

ariva.de ©

Es genügt nicht, keine Gedanken zu haben, man muss auch unfähig sein, sie auszudrücken.  

16.05.07 16:22

227 Postings, 5210 Tage calyritter_die_Ratteudo, du bist der BESTE mann an board...

muhhahahahahaahahahahahahahahahahaahaahahaahhhahahahaahahahahahaa­hahahaaahhaahaahahahahaa
muhhahahahahaahahahahahahahahahahaahaahahaahhhahahahaahahahahahaa­hahahaaahhaahaahahahahaa
muhhahahahahaahahahahahahahahahahaahaahahaahhhahahahaahahahahahaa­hahahaaahhaahaahahahahaa
muhhahahahahaahahahahahahahahahahaahaahahaahhhahahahaahahahahahaa­hahahaaahhaahaahahahahaa  

09.07.07 15:09

730 Postings, 5364 Tage OttomanRosendahlCalypte Begins U.S. Initiative

 

Calypte Begins U.S. Initiative

Monday July 9, 8:30 am ET

Company Secures Manufacturing/Headquarters Facility in Portland Oregon


LAKE OSWEGO, Ore., July 9 /PRNewswire-FirstCall/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC - News), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV) announced today that it has leased an 11,000+ square foot site located in Portland, Oregon. The site permits the consolidation of its research laboratory and administrative functions under one roof and will become the Company's new headquarters location. The site also provides manufacturing space which the Company plans to utilize to build pilot lots for clinical trials in the U.S. The Company expects these studies to be a prelude for submitting a formal application for approval with the U.S. Food and Drug Administration ("FDA").


"This facility is our first step in reestablishing our presence in the U.S. diagnostic test market and moving toward approval of our Aware(TM) HIV- 1/2 oral test in the U.S. We plan to start by commencing the process of filing for FDA approval of an oral fluid test for professional use," stated Roger Gale, Calypte's Chairman and Chief Executive Officer. "One of the uses of funds from the recently-completed PIPE is to advance our efforts to market our oral fluid tests in the U.S. market. Calypte has invested over $3 million to acquire technology and equipment to take advantage of this opportunity."

"While multiple outcomes are possible, our objective for beginning the FDA regulatory process is to ultimately receive approval for manufacturing and distribution of an over-the-counter ("OTC") oral fluid HIV diagnostic test in the U.S.", Mr. Gale concluded.

Calypte plans to occupy its new facility in September 2007.


About U.S. HIV/Aids:

The U.S. is the largest market for HIV diagnostic tests in the world, with 2005 revenues for screening tests estimated at $165 million. An FDA advisory panel has recently announced its support for having an OTC test available in the U.S. In September 2006, the CDC updated its HIV testing guidelines, specifically recognizing the benefits of rapid tests in timely communicating HIV status to patients. The CDC's revised recommendations include routine HIV testing for patients in all health-care settings after the patient is notified that testing will be performed unless the patient declines (opt-out screening); at least annual testing for persons at high risk for HIV infections; and routine opt-out screening for all pregnant women.

About Calypte Biomedical:

Calypte Biomedical Corporation (www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV-1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.



Company Contact: Investor Relations Contact:
Richard Brounstein, Tim Clemensen,
Executive Vice President Rubenstein Investor Relations
(971) 204-0282 Phone: (212) 843-9337
email: rbrounstein@calypte.com email: tclemensen@rubensteinir.com

 

11.07.07 15:08

93 Postings, 5589 Tage SylviaOb´s hilft??

Calypte Announces India Approval
DCAI Regulatory Approval Received for the Aware(TM) HIV-1/2 Oral Fluid Rapid Test
LAKE OSWEGO, Ore., July 11, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CBMC), medical diagnostic tests manufacturer for the rapid detection of antibodies to the human immunodeficiency virus (HIV) announced today that it has received registration and marketing approval for its Aware(TM) HIV-1/2 OMT (oral fluid) rapid test in India from the Central Drugs Standard Control Organisation, commonly referred to as the Drug Control Authority of India ("DCAI").
Roger Gale, Calypte's Chairman and Chief Executive Officer, stated, "As has been highlighted in recent news reports, India is at the forefront in the fight against HIV/AIDS and we have seen strong interest in our oral fluid tests from both the Government and private sectors. A Calypte team has just returned from India where we have begun putting in place the infrastructure to access and build on this important business opportunity. We expect the market for HIV diagnostic testing in India to grow significantly in the next few years."

Mr. Gale continued, "This DCAI approval is a significant milestone in the advancement of our business; a very exciting time for all of us at the Company. Once our non-invasive HIV diagnostic tests gain market acceptance, we anticipate significant growth in market share of such tests. In addition to creating a distribution network, we expect to establish both research and manufacturing operations in India. While we will initially enter the Indian market with our HIV-1/2 oral fluid rapid test, we are also considering introducing our Aware(TM) HIV-1/2 rapid tests using both blood and urine samples to complement the current oral fluid test. India is also a logical center for development of Calypte's new products."

About India:

India has a population of over 1.1 billion, second only to China. According to recently published 2006 estimates by the National AIDS Control Organization or NACO, supported by both UNAIDS and WHO, India has an estimated 2.5 million HIV infections, ranking third behind South Africa and Nigeria for the highest number of HIV/AIDS infected people. Mr. Naresh Dayal, Secretary Health and Chair of the National AIDS Control Board said, " ... we cannot be complacent. The steady and slow spread of the HIV infection is a worrying factor."

The announcement of these new HIV estimates coincides with the launch of a 5-year, $2.8 billion AIDS campaign by the Government of India to prevent the spread of the virus among the country's large under-25 population. Calypte believes that a simple and cost effective non-invasive rapid test is an ideal solution to safely and quickly identify HIV/AIDS patients for treatment and care in large-scale programs such at this.

About Calypte Biomedical:

Calypte Biomedical Corporation (http://www.calypte.com) is a U.S.-based healthcare company focused on the development and commercialization of rapid testing products for sexually transmitted diseases such as the Aware(TM) HIV- 1/2 OMT test that are suitable for use at the point of care and at home. Calypte believes there is a significant need for rapid detection of such diseases globally to control their proliferation, particularly in developing countries, which lack the medical infrastructure to support laboratory-based testing. Calypte believes that testing for HIV and other sexually transmitted infectious diseases may make important contributions to public health, and could increase the likelihood of treating those with undetected HIV and other sexually transmitted diseases.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended. Those statements include statements regarding the intent, belief or current expectations of the Company and its management. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, the Company's ability to obtain additional financing, if and as needed, and access funds from its existing financing arrangements that will allow it to continue its current and future operations and whether demand for its test products in domestic and international markets will generate sufficient revenues to achieve positive cash flow and profitability. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-KSB for the year ended December 31, 2006 and its subsequent filings with the SEC.

    Company Contact:
    Richard Brounstein, Executive Vice President
    (971) 204-0282
    email: rbrounstein@calypte.com

    Investor Relations Contact:
    Tim Clemensen,
    Rubenstein Investor Relations
    (212) 843-9337
    email: tclemensen@rubensteinir.com


SOURCE Calypte Biomedical Corporation

Richard Brounstein, Executive Vice President, of Calypte Biomedical Corporation,
+1-971-204-0282, or rbrounstein@calypte.com; Investor Relations, Tim Clemensen,
+1-212-843-9337, or tclemensen@rubensteinir.com, for Calypte Biomedical Corporation

http://www.calypte.com


 

11.07.07 15:17

730 Postings, 5364 Tage OttomanRosendahlwarum nicht ???

11.07.07 15:57

93 Postings, 5589 Tage SylviaVielleicht weil es in der Vergangenheit

nie geholfen hat?

Es würde mich ja freuen, aber mal schauen ...


S.  

11.07.07 16:00

730 Postings, 5364 Tage OttomanRosendahlkönnte dies der Startschuß für Calypte sein ??

19.07.07 14:46

730 Postings, 5364 Tage OttomanRosendahlHier einige Höhepunkte aus dem CapStone Show


und eure Meinungen dazu:


 
Angehängte Grafik:
slide_0003_full.jpg (verkleinert auf 49%) vergrößern
slide_0003_full.jpg

19.07.07 14:47
 
Angehängte Grafik:
slide_0004_full.jpg (verkleinert auf 49%) vergrößern
slide_0004_full.jpg

19.07.07 14:47

5531 Postings, 5707 Tage gindantscalypte dreht wieder mal rauf

immer schön rauf und runter oder??  

19.07.07 14:47
 
Angehängte Grafik:
slide_0005_full.jpg (verkleinert auf 49%) vergrößern
slide_0005_full.jpg

19.07.07 14:48
 
Angehängte Grafik:
slide_0006_full.jpg (verkleinert auf 49%) vergrößern
slide_0006_full.jpg

19.07.07 14:49
 
Angehängte Grafik:
slide_0007_full.jpg (verkleinert auf 49%) vergrößern
slide_0007_full.jpg

19.07.07 14:49
 
Angehängte Grafik:
slide_0008_full.jpg (verkleinert auf 49%) vergrößern
slide_0008_full.jpg

19.07.07 14:50
 
Angehängte Grafik:
slide_0009_full.jpg (verkleinert auf 49%) vergrößern
slide_0009_full.jpg

19.07.07 14:51
 
Angehängte Grafik:
slide_0010_full.jpg (verkleinert auf 49%) vergrößern
slide_0010_full.jpg

19.07.07 14:51
 
Angehängte Grafik:
slide_0011_full.jpg (verkleinert auf 49%) vergrößern
slide_0011_full.jpg

19.07.07 14:52
 
Angehängte Grafik:
slide_0012_full.jpg (verkleinert auf 49%) vergrößern
slide_0012_full.jpg

19.07.07 14:52
 
Angehängte Grafik:
slide_0014_full.jpg (verkleinert auf 49%) vergrößern
slide_0014_full.jpg

19.07.07 14:53
 
Angehängte Grafik:
slide_0015_full.jpg (verkleinert auf 49%) vergrößern
slide_0015_full.jpg

19.07.07 14:53
 
Angehängte Grafik:
slide_0016_full.jpg (verkleinert auf 49%) vergrößern
slide_0016_full.jpg

19.07.07 14:54
 
Angehängte Grafik:
slide_0017_full.jpg (verkleinert auf 49%) vergrößern
slide_0017_full.jpg

Seite: 1 | ... | 140 | 141 | 142 |
| 144  
   Antwort einfügen - nach oben

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

Oskar

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
BayerBAY001
NEL ASAA0B733
BioNTechA2PSR2
Apple Inc.865985
TeslaA1CX3T
BYD Co. Ltd.A0M4W9
Deutsche Bank AG514000
Siemens Energy AGENER6Y
PalantirA2QA4J
XiaomiA2JNY1
Daimler AG710000
Amazon906866
CureVacA2P71U
Plug Power Inc.A1JA81
Ballard Power Inc.A0RENB